Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showca...
June 02 2020 - 8:06AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse, not
manage, disease today announced that the company has been selected
to present at the BioNJ COVID-19 Rapid Fire Research Showcase on
Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief
Executive Officer of Caladrius Biosciences, will present an
overview of CLBS119, Caladrius’ CD34+ cell therapy product
candidate targeting repair of COVID-19 induced lung damage.
For more information on BioNJ’s COVID-19 Rapid
Fire Research Showcase, please click here.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse, not manage, disease. We are
developing a first- in-class cell therapy product that is based on
the notion that our body contains finely tuned mechanisms for
self-repair. Our technology leverages and enables these mechanisms
in the form of specific cells, using formulations and modes of
delivery unique to each medical indication.
The Company's current product candidates include
CLBS119, a CD34+ cell therapy product candidate for the repair of
lung damage found in patients with severe COVID-19 infection who
experienced respiratory failure, for which the Company plans to
initiate a clinical trial in the coming months as well as three
developmental treatments for ischemic diseases based on its CD34+
cell therapy platform: CLBS12, recipient of SAKIGAKE designation
and eligible for early conditional approval in Japan for the
treatment of critical limb ischemia ("CLI") based on the results of
an ongoing clinical trial; CLBS16, the subject of a recently
completed positive Phase 2 clinical trial in the U.S. for the
treatment of coronary microvascular dysfunction ("CMD"); and
CLBS14, a Regenerative Medicine Advanced Therapy ("RMAT")
designated therapy for which the Company has finalized with the
U.S. Food and Drug Administration (the "FDA") a protocol for a
Phase 3 confirmatory trial in subjects with no-option refractory
disabling angina ("NORDA"). For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John
Menditto Vice President, Investor Relations and Corporate
Communications Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:W2O GroupChristiana PascalePhone:
+1-212-257-6722Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024